Novo drug ziltivekimab meets primary endpoint in inflammatory biomarker trial
According to Novo Nordisk, the trial showed a significant reduction in several inflammatory biomarkers associated with atherosclerosis in people with advanced chronic kidney disease.
BY RITZAU FINANS, TRANSLATED BY CATHERINE BRETT
Novo Nordisk has released the results of its phase II trial of ziltivekimab, 'Rescue'. The drug, which is taken monthly, attained its primary goal of reducing inflammatory biomarkers associated with atherosclerosis (hardened arteries, -ed.) in people with advanced chronic kidney disease.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Chinese authorities have approved Novo Nordisk's Ozempic
For subscribers
